AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2195567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 328139 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 0
Study 328139 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant trials incorporating radiation
Number of subjects: 0
Study 328139 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone or in combination with chemotherapy
Number of subjects: 0
Study 328139 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy followed by immunotherapy
Number of subjects: 0
Study 31590189 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated 2 h light‐intensity treadmill desk walking
Number of subjects: 21
Study 31590189 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 21
Study 28924366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine in combination with fentanyl-based IV-PCA (dIV-PCA group)
Number of subjects: 171
Study 28924366 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional thoracic E-PCA (E-PCA group)
Number of subjects: 171
Study 28924366 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-based IV-PCA only (IV-PCA group)
Number of subjects: 171
Study 25264671 — intervention group
Group type: EXPERIMENTAL
Intervention: Vented mouthguard (VentMG)
Number of subjects: 15
Study 25264671 — intervention group
Group type: COMPARATOR
Intervention: Traditional mouthguard (TradMG)
Number of subjects: 15
Study 25264671 — intervention group
Group type: COMPARATOR
Intervention: Control (no mouthguard)
Number of subjects: 15
Study 23589703 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promoting behaviors
Number of subjects: 150
Study 23589703 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting resilience in high-risk group
Number of subjects: 150
Study 23589703 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting resilience in early CKD group
Number of subjects: 150
Study 23589703 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting resilience in pre-ESRD group
Number of subjects: 150
Study 23589703 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 150
Study 21863672 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)‐adjuvanted H5N1 influenza vaccine
Number of subjects: 0
Study 21863672 — intervention group
Group type: COMPARATOR
Intervention: Non‐adjuvanted H5N1 vaccine formulations
Number of subjects: 0
Study 18671296 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral tape (MUT) insertion
Number of subjects: 100
Study 18671296 — intervention group
Group type: COMPARATOR
Intervention: Preoperative URP measurement
Number of subjects: 100
Study 17301074 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 7707
Study 17301074 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 7707
Study 15129754 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual training
Number of subjects: 0
Study 15129754 — intervention group
Group type: COMPARATOR
Intervention: Auditory training
Number of subjects: 0
Study 11565978 — intervention group
Group type: EXPERIMENTAL
Intervention: Accident terminology questionnaire
Number of subjects: 183
Study 11565978 — intervention group
Group type: COMPARATOR
Intervention: Injury terminology questionnaire
Number of subjects: 183
Study 9692166 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole (alb) 600 mg + ivermectin (iver) 400 micrograms/kg
Number of subjects: 50
Study 9692166 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole (alb) 600 mg
Number of subjects: 50
Study 9692166 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole (alb) 600 mg + diethylcarbamazine (DEC) 6 mg/kg
Number of subjects: 50
Study 9692166 — intervention group
Group type: EXPERIMENTAL
Intervention: diethylcarbamazine (DEC) 6 mg/kg + ivermectin (iver) 400 micrograms/kg
Number of subjects: 50
Study 9692166 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole (alb) + diethylcarbamazine (DEC)
Number of subjects: 50
Study 9692166 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole (alb) + ivermectin (iver)
Number of subjects: 50
Study 9692166 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 50
Study 7599511 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45 mg daily for 60 days)
Number of subjects: 22
Study 7599511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3075602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid ingestion during exercise
Number of subjects: 8
Study 3075602 — intervention group
Group type: COMPARATOR
Intervention: Placebo during exercise
Number of subjects: 8
Study 31721978 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor copayment reduction intervention (vouchers waiving copayments for 1 year)
Number of subjects: 8373
Study 31068500 — intervention group
Group type: EXPERIMENTAL
Intervention: NPVS-R instrument
Number of subjects: 329
Study 27037007 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I interpretation of cases with preceding diagnosis of ductal carcinoma in situ (DCIS) or invasive cancer
Number of subjects: 152
Study 27037007 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II interpretation of cases with preceding diagnosis of ductal carcinoma in situ (DCIS) or invasive cancer
Number of subjects: 152
Study 25551562 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 48
Study 25551562 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing + Normative Feedback (MI+NF)
Number of subjects: 48
Study 23474238 — intervention group
Group type: EXPERIMENTAL
Intervention: What happens next training
Number of subjects: 233
Study 23474238 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert commentary training
Number of subjects: 233
Study 23474238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid commentary training (expert plus self‐generated commentaries)
Number of subjects: 233
Study 23474238 — intervention group
Group type: EXPERIMENTAL
Intervention: Full training package (what happens next plus hybrid commentary training)
Number of subjects: 233
Study 23474238 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 233
Study 23474238 — intervention group
Group type: EXPERIMENTAL
Intervention: Full training package
Number of subjects: 233
Study 21455043 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized comprehensive self-management intervention
Number of subjects: 173
Study 21455043 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 173
Study 17653851 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine (TX)
Number of subjects: 209
Study 17653851 — intervention group
Group type: COMPARATOR
Intervention: doxorubicin/cyclophosphamide (AC)
Number of subjects: 209
Study 17653851 — intervention group
Group type: EXPERIMENTAL
Intervention: both TX and AC
Number of subjects: 209
Study 17171602 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-Prevention Plan
Number of subjects: 0
Study 17171602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Number of subjects: 0
Study 17171602 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy
Number of subjects: 0
Study 17171602 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment
Number of subjects: 0
Study 17171602 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Psychoeducation
Number of subjects: 0
Study 15103479 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist environment dressing
Number of subjects: 0
Study 15103479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing, wound cleansing, and debridement
Number of subjects: 0
Study 15103479 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotic treatment
Number of subjects: 0
Study 15103479 — intervention group
Group type: COMPARATOR
Intervention: Topical negative pressure, maggot therapy, electromagnetic therapy, therapeutic ultrasound, growth factors
Number of subjects: 0
Study 11035391 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanotan II
Number of subjects: 20
Study 11035391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9355585 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper tape measurements
Number of subjects: 49
Study 9355585 — intervention group
Group type: COMPARATOR
Intervention: Cloth tape measurements
Number of subjects: 49
Study 1288660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose levodopa, bromocriptine, or a combination of both drugs
Number of subjects: 107
Study 1288660 — intervention group
Group type: COMPARATOR
Intervention: Control group (spouses, friends of PD patients, community volunteers)
Number of subjects: 107
Study 3936760 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 (8 ng/kg/min)
Number of subjects: 40
Study 3936760 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2
Number of subjects: 40
Study 3936760 — intervention group
Group type: COMPARATOR
Intervention: Control (glycine buffer)
Number of subjects: 40
Study 31561360 — intervention group
Group type: EXPERIMENTAL
Intervention: MILD[+] patients
Number of subjects: 1198
Study 31561360 — intervention group
Group type: COMPARATOR
Intervention: MILD[-] patients
Number of subjects: 1198
Study 31561360 — intervention group
Group type: COMPARATOR
Intervention: Patients with amyloid[-]
Number of subjects: 1198
Study 29373734 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment for 36 months
Number of subjects: 308
Study 29373734 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 36 months
Number of subjects: 308
Study 27832623 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at six points (ST34, SP10, SP9, ST36, ST35, EX‐LE4)
Number of subjects: 132
Study 27832623 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at four points (ST34, SP10, ST35, EX‐LE5)
Number of subjects: 132
Study 27832623 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at two points (ST35, EX‐LE4)
Number of subjects: 132
Study 27832623 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 132
Study 25080051 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 ppm)
Number of subjects: 50
Study 25080051 — intervention group
Group type: COMPARATOR
Intervention: Sham inhaled nitric oxide administration
Number of subjects: 50
Study 22924950 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA + bexarotene
Number of subjects: 93
Study 22924950 — intervention group
Group type: COMPARATOR
Intervention: PUVA alone
Number of subjects: 93
Study 20673983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - Budesonide
Number of subjects: 1041
Study 20673983 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated children)
Number of subjects: 1041
Study 18343541 — intervention group
Group type: EXPERIMENTAL
Intervention: 23‐valent pneumococcal polysaccharide vaccine
Number of subjects: 1298
Study 15641062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (methotrexate + etanercept)
Number of subjects: 682
Study 15641062 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 682
Study 15641062 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (methotrexate or etanercept)
Number of subjects: 682
Study 12130441 — intervention group
Group type: EXPERIMENTAL
Intervention: MR cholangiopancreatography
Number of subjects: 26
Study 12130441 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 26
Study 11465011 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual and group psychotherapy, cognitive-behavioral therapy, 12-step programmes
Number of subjects: 0
Study 11465011 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin (5-hydroxytryptamine; 5-HT) re-uptake inhibitors
Number of subjects: 0
Study 11465011 — intervention group
Group type: EXPERIMENTAL
Intervention: Debt consolidation and credit counselling
Number of subjects: 0
Study 11465011 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help books
Number of subjects: 0
Study 9459044 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg enteric-coated tablet
Number of subjects: 40
Study 9459044 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg capsule
Number of subjects: 40
Study 7963448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 708
Study 3306891 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ASA and 1 g sucralfate four times daily
Number of subjects: 16
Study 3306891 — intervention group
Group type: COMPARATOR
Intervention: 1 g ASA four times daily and placebo tablets
Number of subjects: 16
Study 3306891 — intervention group
Group type: EXPERIMENTAL
Intervention: No drugs administered
Number of subjects: 16
Study 31629621 — intervention group
Group type: EXPERIMENTAL
Intervention: LCS Complete DUOFIX (porous coating plus HA and pegs)
Number of subjects: 197
Study 31629621 — intervention group
Group type: COMPARATOR
Intervention: LCS Complete POROCOAT (porous coating only)
Number of subjects: 197
Study 29880291 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and abiraterone
Number of subjects: 142
Study 29880291 — intervention group
Group type: COMPARATOR
Intervention: Placebo and abiraterone
Number of subjects: 142
Study 28118620 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of urine albumin-to-creatinine ratio (UACR)
Number of subjects: 2620
Study 28118620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower estimated glomerular filtration rate (eGFR)
Number of subjects: 2620
Study 28118620 — intervention group
Group type: COMPARATOR
Intervention: Control for covariates
Number of subjects: 2620
Study 26162632 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 1000mg twice at 2 weeks interval
Number of subjects: 175
Study 24001083 — intervention group
Group type: EXPERIMENTAL
Intervention: fosphenytoin (fPHT)
Number of subjects: 200
Study 24001083 — intervention group
Group type: EXPERIMENTAL
Intervention: lacosamide
Number of subjects: 200
Study 21700754 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 73
Study 21700754 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 73
Study 18086726 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 17
Study 18086726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16868064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (strict blood glucose control to normoglycemia with insulin)
Number of subjects: 451
Study 16868064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensive insulin therapy)
Number of subjects: 451
Study 16868064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration (replacement dose)
Number of subjects: 451
Study 12757066 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard needle aspiration (Group A)
Number of subjects: 16
Study 12757066 — intervention group
Group type: COMPARATOR
Intervention: Nylon probing (Group B)
Number of subjects: 16
Study 11097068 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for Parenthood intervention
Number of subjects: 190
Study 11097068 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care only
Number of subjects: 190
Study 9086340 — intervention group
Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 109
Study 9086340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized 17 beta‐estradiol/oral sequential dydrogesterone
Number of subjects: 109
Study 9086340 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol/oral sequential dydrogesterone
Number of subjects: 109
Study 9086340 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tibolone
Number of subjects: 109
Study 8461075 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-naproxen
Number of subjects: 87
Study 8461075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 29558923 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive intervention (1-in-10 chance of winning a £50 shopping voucher for returning a signed consent form)
Number of subjects: 242
Study 29558923 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive intervention
Number of subjects: 242
Study 27805982 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) followed by a 12-week exercise intervention
Number of subjects: 12
Study 27805982 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 12
Study 26604653 — intervention group
Group type: EXPERIMENTAL
Intervention: BS capsules containing glucoraphanin (GR) for 2 months
Number of subjects: 52
Study 26604653 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 52
Study 26604653 — intervention group
Group type: EXPERIMENTAL
Intervention: BS extract in animal model
Number of subjects: 52
Study 23164309 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus daily enemas for 2 weeks
Number of subjects: 71
Study 23164309 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 71
Study 21823381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block with bupivacaine
Number of subjects: 55
Study 21823381 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration of the skin and subcutaneous tissue
Number of subjects: 55
Study 21823381 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline TAP block)
Number of subjects: 55
Study 18655817 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ingestion of a strong-gelling sodium alginate formulation for 7 days
Number of subjects: 68
Study 18655817 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 17152782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bileaflet valve
Number of subjects: 37
Study 17152782 — intervention group
Group type: COMPARATOR
Intervention: Monoleaflet valve
Number of subjects: 37
Study 17152782 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis diameter
Number of subjects: 37
Study 12689798 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month integrated dietary/breast health intervention
Number of subjects: 256
Study 12689798 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 256
Study 10972603 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration performed with a polysulfone hemofilter during rewarming on cardiopulmonary bypass
Number of subjects: 26
Study 10972603 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure (Control)
Number of subjects: 26
Study 8786777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate (1 g by intravenous infusion starting 30 to 90 minutes before endoscopy and continuing for 12 hours afterward)
Number of subjects: 418
Study 8786777 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate
Number of subjects: 418
Study 8786777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mannitol and sodium chloride administered in the same fashion)
Number of subjects: 418
Study 8786777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 1440818 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and heavy S. haematobium infection
Number of subjects: 422
Study 1440818 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of splenomegaly
Number of subjects: 422
Study 1440818 — intervention group
Group type: EXPERIMENTAL
Intervention: History of treated infection
Number of subjects: 422
Study 1440818 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of periportal fibrosis
Number of subjects: 422
Study 3994929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Number of subjects: 40
Study 3994929 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose
Number of subjects: 40
Study 3994929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann's solution
Number of subjects: 40
Study 3994929 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 31640315 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-exercise programme (BE)
Number of subjects: 69
Study 31640315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fartlek-training (FT)
Number of subjects: 69
Study 31640315 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-training (IT)
Number of subjects: 69
Study 31640315 — intervention group
Group type: COMPARATOR
Intervention: Constant-training (CT)
Number of subjects: 69
Study 29690714 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 kVp + ADMIRE (group 1)
Number of subjects: 74
Study 29690714 — intervention group
Group type: EXPERIMENTAL
Intervention: linear blending + ADMIRE (group 2)
Number of subjects: 74
Study 29690714 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp + SAFIRE (group 3)
Number of subjects: 74
Study 25881568 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) autograft ACL reconstruction
Number of subjects: 330
Study 25881568 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-stranded hamstring tendon (HT) autograft ACL reconstruction
Number of subjects: 330
Study 25881568 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) hamstring autograft ACL reconstruction
Number of subjects: 330
Study 24970272 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (130/0.4) + 500 ml of Ringer's lactate (HES group)
Number of subjects: 167
Study 24970272 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (1000 ml) (RL group)
Number of subjects: 167
Study 22641931 — intervention group
Group type: EXPERIMENTAL
Intervention: Support person present
Number of subjects: 129
Study 22641931 — intervention group
Group type: COMPARATOR
Intervention: No support person present (Control)
Number of subjects: 129
Study 22641931 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers present with a patient
Number of subjects: 129
Study 20186402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined kinetic and visual guidance
Number of subjects: 39